Pharmaceutical Technology | Drug Development News & Views Updated Daily

Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Advertise with us

AstraZeneca divests Atacand’s European rights for $210m

AstraZeneca has signed an agreement to sell the European commercial rights for its Atacand (candesartan...
Read More...

AstraZeneca divests Atacand’s European rights for $210m

Supporting mental health in a business environment

Download a free 10 page preview of our Mergers & Acquisitions in TMT – Thematic Research 2019 Report